Alopecia areata causes the immune system to attack hair follicles, creating smooth, round patches of hair loss on the scalp or body. About 2% of people develop it at some point, often starting in childhood or young adulthood. Until 2022, no FDA-approved treatments existed; now two JAK inhibitors are approved for severe cases.
What's actually going on in research
Trials are testing oral and topical JAK inhibitors at different doses and for milder disease, biologics that block specific immune signals like IL-15, and combination approaches. Researchers are also studying what triggers the immune attack, why some people respond better than others, and whether earlier treatment prevents progression to more extensive hair loss.
JAK inhibitors expanding
Baricitinib and ritlecitinib are FDA-approved for severe alopecia areata, and trials are testing whether lower doses work for patchy disease. Topical JAK inhibitors may offer an option for people with limited hair loss who want to avoid systemic treatment.
Biologics targeting immune signals
Studies are testing drugs that block IL-15, IL-2, and other immune proteins involved in the attack on hair follicles. These may work for people who don't respond to JAK inhibitors or who can't tolerate them.
Combination strategies
Some trials are pairing immune-suppressing drugs with treatments that stimulate hair growth directly. The goal is to quiet the immune attack while encouraging follicles to regrow hair.
What to know before you search
Eligibility typically depends on how much scalp hair has been lost, how long the hair loss has lasted, and whether you've tried other treatments like steroid injections.
What types of trials are currently open
- JAK inhibitor trials — Testing oral and topical JAK inhibitors for different severities of alopecia areata, often comparing doses or treatment durations.
- Biologic trials — Testing monoclonal antibodies that block specific immune pathways thought to drive hair loss in alopecia areata.
- Combination trials — Pairing immune-modulating drugs with topical hair growth stimulants to see if the combination produces better regrowth.
- Pediatric trials — Testing treatments specifically in children and adolescents, who make up a large portion of people with alopecia areata.
- Natural history studies — Following people over time to understand how alopecia areata progresses, what predicts regrowth, and how quality of life is affected.
Recently added Alopecia Areata trials
Comparative Effectiveness of Intralesional Injection of Triamcinolone Acetonide vs. Microneedling With Local Application of Triamcinolone Acetonide in the Treatment of Alopecia Areata
Brief Summary The goal of this clinical trial is to learn which treatment works better for people with alopecia areata, a condition that causes patchy hair loss. The study will compare two commonly used treatments to see which one leads to better hair regrowth and fewer side effects. The main questions this study aims to answer are: Does injecting triamcinolone acetonide into the skin lead to better hair regrowth than microneedling with topical triamcinolone acetonide? Are there any side effects linked to these treatments? Researchers will compare two groups of participants. One group will receive intralesional injections of triamcinolone acetonide. The other group will receive microneedling followed by the local application of triamcinolone acetonide. The results will be compared to see which treatment works better for alopecia areata. Participants will: Be examined by the research team to confirm the diagnosis of alopecia areata Receive one of the two treatments as part of the study Attend follow-up visits so researchers can check hair regrowth and monitor for side effects
Take an experimental treatment being tested for male health
The study is designed to validate efficacy and long term safety of PP405.
Find Alopecia Areata trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.